Binh T Vu

US Patent:

6734302, May 11, 2004

Filed:

Dec 11, 2002

Appl. No.:

10/316695

Inventors:

Norman Kong - West Caldwell NJ
Emily Aijun Liu - Nutley NJ
Binh Thanh Vu - North Caldwell NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D23322

US Classification:

544139, 544370, 546210, 5483341

Abstract:

The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

US Patent:

7157455, Jan 2, 2007

Filed:

Feb 2, 2004

Appl. No.:

10/770379

Inventors:

David Joseph Bartkovitz - Nutley NJ, US
Qingjie Ding - Bridgewater NJ, US
Nan Jiang - Fairfield NJ, US
Allen John Lovey - North Caldwell NJ, US
John Anthony Moliterni - Staten Island NY, US
Binh Thanh Vu - North Caldwell NJ, US
Peter Michael Wovkulich - Nutley NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 401/12
C07D 403/12
C07D 413/12
A61K 31/4468
C07D 239/42

US Classification:

5142358, 51425218, 514275, 544122, 544295, 544323, 544324, 544325

Abstract:

Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.

US Patent:

7615634, Nov 10, 2009

Filed:

Jun 20, 2006

Appl. No.:

11/471001

Inventors:

David Joseph Bartkovitz - Nutley NJ, US
Qingjie Ding - Bridgewater NJ, US
Nan Jiang - Fairfield NJ, US
Allen John Lovey - North Caldwell NJ, US
John Anthony Moliterni - Staten Island NY, US
Binh Thanh Vu - North Caldwell NJ, US
Peter Michael Wovkulich - Nutley NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 239/47
C07D 239/48

US Classification:

544317, 544325, 544329, 544334

Abstract:

Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.

US Patent:

7625895, Dec 1, 2009

Filed:

Mar 18, 2008

Appl. No.:

12/050235

Inventors:

Romyr Dominique - Wayne NJ, US
Qi Qiao - Bloomfield NJ, US
Binh Thanh Vu - North Caldwell NJ, US

Assignee:

Hoffmann-Le Roche Inc. - Nutley NJ

International Classification:

A61K 31/437
C07D 471/04
A61K 31/5377
A61P 35/00
C07D 413/14

US Classification:

5142358, 514300, 546121, 544121

Abstract:

p-00010000.

US Patent:

8513239, Aug 20, 2013

Filed:

Oct 9, 2008

Appl. No.:

12/248095

Inventors:

David Joseph Bartkovitz - Nutley NJ, US
Jianping Cai - West Caldwell NJ, US
Hongju Li - Edison NJ, US
Allen John Lovey - North Caldwell NJ, US
Binh Thanh Vu - North Caldwell NJ, US
Chunlin Zhao - Livingston NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

A61K 31/55
A61K 31/03
A61K 31/44
A61K 31/535
A61K 31/505
C07D 243/06
C07D 243/14
C07D 279/10
C07D 413/08
C07D 403/08
C07D 239/02
C07D 215/02

US Classification:

514221, 51421018, 514218, 514235, 514269, 514278, 540492, 540573, 544 582, 544121, 544295, 544319, 546 16, 546194

Abstract:

There are provided compounds of the formula.

US Patent:

20040204410, Oct 14, 2004

Filed:

Apr 28, 2004

Appl. No.:

10/835021

Inventors:

Norman Kong - West Caldwell NJ, US
Emily Liu - West Caldwell NJ, US
Binh Vu - North Caldwell NJ, US

International Classification:

C07D413/02
C 07D 4 3/02
A61K031/5377
A61K031/496
A61K031/4172

US Classification:

514/235500, 514/254050, 514/400000, 544/139000, 544/370000, 548/335500

Abstract:

The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

US Patent:

20130244958, Sep 19, 2013

Filed:

Mar 5, 2013

Appl. No.:

13/785267

Inventors:

Xin-Jie Chu - Shanghai, CN
Binh Thanh Vu - North Caldwell NJ, US
Chunlin Zhao - Shanghai, CN
Daniel Fishlock - Basel, CH

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 403/12
C07F 9/572
C07H 15/26
C07D 207/16

US Classification:

514 23, 548537, 514423, 548413, 514 91, 544372, 51425401, 544141, 5142355, 544 582, 5142278, 536 53

Abstract:

There are provided compounds of the formulawherein X, Y, Z, R, R, Rand Rare as described hereinand enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

US Patent:

20130324531, Dec 5, 2013

Filed:

May 29, 2013

Appl. No.:

13/904153

Inventors:

Xin-Jie Chu - Shanghai, CN
George Kenneth Ehrlich - Bronx NY, US
Jin-Jun Liu - Warren Township NJ, US
Hanspeter Michel - Bloomfield NJ, US
Binh Thanh Vu - North Caldwell NJ, US
Chunlin Zhao - Shanghai, CN

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 207/16
C07H 17/02
C07D 401/12
C07F 9/572
C07D 405/12

US Classification:

5142355, 548537, 548413, 548517, 546208, 544372, 546117, 544141, 514423, 514326, 514300, 514422, 514 91, 51425401, 536 174, 514 25

Abstract:

There are provided compounds of the formulawherein X, Y, Z, R, Rand Rare as described hereinand enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.